California-based Resmed (RMD) makes medical equipment and devices for the treatment of sleep apnea. It sells its products around the world. Resmed recently introduced a new sleep apnea device called AirSense 11, which it is initially rolling out in the U.S. Let’s take a look at Resmed’s latest financial performance and risk factors. Resmed’s Fiscal Q4 and 2021 Financial Results The company reported a 14% year-over-year increase in revenue to $876.1 million for its Fiscal 2021 fourth-quarter ended June 30. That beat consensus estimates of $783.18 million. Adjusted EPS of $1.35 increased from $1.33 a year ago and beat consensus estimates of $1.28.
https://www.tipranks.com/news/what-do-resmeds-earnings-and-newly-added-risk-factor-tell-investors?utm_source=advfn.com&utm_medium=referral
ResMed (NYSE:RMD)
Gráfico Histórico do Ativo
De Set 2021 até Out 2021 Click aqui para mais gráficos ResMed.
ResMed (NYSE:RMD)
Gráfico Histórico do Ativo
De Out 2020 até Out 2021 Click aqui para mais gráficos ResMed.